Characterization of health-related quality of life based on the EQ-5D-5L questionnaire in head-and-neck cancer patients undergoing modern radiotherapy

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Vokes EE, Weichselbaum RR, Lippman SM. Head and neck cancer. N Engl J Med. 1993;328(3):184–194.
   PubMed Web of Science ®Google Scholar
• Logan RM. Advances in understanding of toxicities of treatment for head and neck cancer. Oral Oncol. 2009;45(10):844–848.
   PubMed Web of Science ®Google Scholar
• Liao LJ, Hsu WL, Lo WC, et al. Health-related quality of life and utility in head and neck cancer survivors. BMC Cancer. 2019;19(1):425.
   PubMed Web of Science ®Google Scholar
• Van den Bogaert W, Van der Leest A, Rijnders A, et al. Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer? Radiother Oncol. 1995;36(3):177–182.
   PubMed Web of Science ®Google Scholar
• van Lier LI, Bosmans JE, van Hout HPJ, et al. Consensus-based cross-European recommendations for the identification, measurement and valuation of costs in health economic evaluations: a European Delphi study. Eur J Health Econ. 2018;19(7):993–1008.
   PubMed Web of Science ®Google Scholar
• Verma V, Simone CB 2nd, Mishra MV. Quality of life and patient-reported outcomes following proton radiation therapy: a systematic review. J Natl Cancer Inst. 2018;110(4):341–353.
   PubMedGoogle Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
   PubMed Web of Science ®Google Scholar
• EunetHta Joint Action WPS, Heintz E, Gerber-Grote A, et al. Is there a european view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUnetHTA partner countries. Pharmacoeconomics. 2016;34(1):59–76.
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr., Neumann PJ, Willke RJ, et al. A health economics approach to US value assessment frameworks-summary and recommendations of the ISPOR special task force report [7]. Value Health. 2018;21(2):161–165.
   PubMed Web of Science ®Google Scholar
• Ludwig K, Graf von der Schulenburg JM, Greiner W. German value set for the EQ-5D-5L. Pharmacoeconomics. 2018;36(6):663–674.
   PubMed Web of Science ®Google Scholar
• Huber MB, Felix J, Vogelmann M, et al. Health-related quality of life of the general german population in 2015: results from the EQ-5D-5L. Int J Environ Res Public Health. 2017;14(4):426.
   PubMed Web of Science ®Google Scholar
• Bernert S, Fernandez A, Haro JM, et al. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries. Value Health. 2009;12(5):750–758.
   PubMed Web of Science ®Google Scholar
• Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4(3):222–231.
   PubMedGoogle Scholar
• Massetti M, Aballea S, Videau Y, et al. A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments. J Mark Access Health Policy. 2015;3.
   Google Scholar
• Ludwig K, von der Schulenburg JG, Greiner W. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study. Health Qual Life Outcomes. 2017;15(1):39.
   PubMed Web of Science ®Google Scholar
• Pickard AS, Law EH, Jiang R, et al. United states valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931–941.
   PubMed Web of Science ®Google Scholar
• Danzon PM, Drummond MF, Towse A, et al. Objectives, budgets, thresholds, and opportunity costs-a health economics approach: an ISPOR special task force report [4]. Value Health. 2018;21(2):140–145.
   PubMed Web of Science ®Google Scholar
• Devlin NJ, Parkin D, Browne J. Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. Health Econ. 2010;19(8):886–905.
   PubMed Web of Science ®Google Scholar
• Verma V, Sprave T, Haque W, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):128.
   PubMed Web of Science ®Google Scholar
• Verma V, Shah C, Rwigema JC, et al. Cost-comparativeness of proton versus photon therapy. Chin Clin Oncol. 2016;5(4):56.
   PubMed Web of Science ®Google Scholar
• Sprave T, Verma V, Sterzing F, et al. Cost-effectiveness of carbon ion radiation therapy for skull base chordoma utilizing long-term (10-Year) outcome data. Anticancer Res. 2018;38(8):4853–4858.
   PubMed Web of Science ®Google Scholar
• Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016;122(10):1483–1501.
   PubMed Web of Science ®Google Scholar
• Rencz F, Gulacsi L, Drummond M, et al. EQ-5D in central and Eastern Europe: 2000–2015. Qual Life Res. 2016;25(11):2693–2710.
   PubMed Web of Science ®Google Scholar
• Harris J. QALYfying the value of life. J Med Ethics. 1987;13(3):117–123.
   PubMed Web of Science ®Google Scholar
• Garau M, Shah KK, Mason AR, et al. Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics. 2011;29(8):673–685.
   PubMed Web of Science ®Google Scholar
• McGregor M, Caro JJ. QALYs: are they helpful to decision makers? Pharmacoeconomics. 2006;24(10):947–952.
   PubMed Web of Science ®Google Scholar
• Nord E. Beyond QALYs: multi-criteria based estimation of maximum willingness to pay for health technologies. Eur J Health Econ. 2018;19(2):267–275.
   PubMed Web of Science ®Google Scholar
• Grochtdreis T, Dams J, Konig HH, et al. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. Eur J Health Econ. 2019;20(6):933–944.
   PubMed Web of Science ®Google Scholar
• Meregaglia M, Cairns J. A systematic literature review of health state utility values in head and neck cancer. Health Qual Life Outcomes. 2017;15(1):174.
   PubMed Web of Science ®Google Scholar
• Giuliani M, Papadakos J, Broadhurst M, et al. The prevalence and determinants of return to work in head and neck cancer survivors. Support Care Cancer. 2019;27(2):539–546.
   PubMed Web of Science ®Google Scholar
• Haehl E, Ruhle A, David H, et al. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? Radiat Oncol. 2020;15(1):31.
   PubMed Web of Science ®Google Scholar
• Budach W, Bolke E, Kammers K, et al. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Radiother Oncol. 2016;118(2):238–243.
   PubMed Web of Science ®Google Scholar
• Sprave T, Ruhle A, Hees K, et al. Radiotherapeutic management of cervical lymph node metastases from an unknown primary site - experiences from a large cohort treated with modern radiation techniques. Radiat Oncol. 2020;15(1):80.
   PubMed Web of Science ®Google Scholar
• Woody NM, Ward MC, Koyfman SA, et al. Adjuvant chemoradiation after surgical resection in elderly patients with high-risk squamous cell carcinoma of the head and neck: a national cancer database analysis. Int J Radiat Oncol Biol Phys. 2017;98(4):784–792.
   PubMed Web of Science ®Google Scholar
• Hinz A, Kohlmann T, Stobel-Richter Y, et al. The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population. Qual Life Res. 2014;23(2):443–447.
   PubMed Web of Science ®Google Scholar
• van de Poll-franse LV, Mols F, Gundy CM, Aaronson NK, et al. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general dutch population. Eur J Cancer. 2011;47(5):667–675.
   PubMed Web of Science ®Google Scholar
• Noel CW, Stephens RF, Su JS, et al. Mapping the EORTC QLQ-C30 and QLQ-H & N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer. Head Neck. 2020;42(9):2277–2286.
   Web of Science ®Google Scholar
• Konnopka A, Koenig HH. The “no problems”-problem: an empirical analysis of ceiling effects on the EQ-5D 5L. Qual Life Res. 2017;26(8):2079–2084.
   PubMed Web of Science ®Google Scholar
• Davies A, Waylen A, Leary S, et al. Assessing the validity of EQ-5D-5L in people with head & neck cancer: does a generic quality of life measure perform as well as a disease-specific measure in a patient population? Oral Oncol. 2020;101:104504.
   PubMed Web of Science ®Google Scholar
• Buchholz I, Thielker K, Feng YS, et al. Measuring changes in health over time using the EQ-5D 3L and 5L: a head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample. Qual Life Res. 2015;24(4):829–835.
   PubMed Web of Science ®Google Scholar
• Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;84(5):1198–1205.
   PubMed Web of Science ®Google Scholar